Corporate Information: Embryome Sciences, Inc. (ES) is a wholly owned subsidiary of BioTime, Inc. (OTCBB:BTIM). The company was organized in December, 2007 as an operating subsidiary of BTIM and its mission is to participate in the emerging field of regenerative medicine known as “embryomics”. “Human embryonic stem cells are capable of becoming all of the thousands of different cell types in the body,” said Michael West, Ph.D., Chief Executive Officer of both ES and BTIM. “And since embryonic stem cells can now be derived in a noncontroversial manner, they are increasingly likely to be utilized in a wide array of future therapies to restore the function of organs damaged by degenerative diseases such as heart failure, stroke, and diabetes. The future challenge for regenerative medicine is to navigate the complexity of human development and manufacture purified populations of desired cell types. Embryomics™ represents the merger of new technologies in the field of genomics with the biology of embryonic stem cells to provide scientists with a detailed “roadmap” of the human developmental tree, the factors to push the cells into desired lineages, and tools to purify the desired cell types.” BioTime believes that the development of products in the embryomics sector may allow Embryome Sciences to commercialize products more quickly, using less capital, than developing therapeutic products from stem cells. Embryome Sciences’ plan is to market its products and services to companies and academic researchers in this growing industry to provide them with the tools they need to attain their goals. Embryome Sciences has launched two kinds of research products this year and plans to launch one more in 2009. The first product is a commercial database that provides the first detailed map of the embryome, thereby aiding researchers in navigating the complexities of human development and in identifying the many hundreds of cell types coming from embryonic stem cells. This map of the human and mouse embryome takes the form of a relational data base that would permit researchers to chart the cell lineages of human development, the genes expressed in those cell types, and antigens present on the cell surface of those cells that can be used in purification. Embryome Sciences launched this web-based database in June, 2008. The new website will also be used to market stem cell research products developed by Embryome Sciences and by other companies. Second, in order to manufacture specific cell types from embryonic stem cells, researchers need to use factors that induce those cells to become a desired cell type. Embryome Sciences plans to develop growth and differentiation factors that can do this, and the first of these products is available for purchase on our website since June, 2008. The third category of near-term embryomics products that Embryome Sciences will pursue, to be launched beginning in 2009, is a line of purification tools useful to researchers in purification and quality control analysis of products in regenerative medicine. BioTime, headquartered in Alameda, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime’s lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ Corp. under exclusive licensing agreements. BioTime has recently entered the field of regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. where it plans to develop new medical and research products using embryonic stem cell technology. Information about BioTime can be found on the web at www.biotimeinc.com. Hextend®, PentaLyte®, and HetaCool® are registered trademarks of BioTime, Inc. Contact us for more info Site Map